PDCD1 and cancer: In patients treated with the anti-PD-1 antibody, by combining PD-L1ES with a clinical model that was constructed using age, sex, smoking history and family history of malignant tumors, the reaction to immunotherapy could be anticipated in a manner more accurate than using PD-L1ES or the clinical model alone as predictors [40].